Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer.
about
Gynecomastia in Patients with Prostate Cancer: A Systematic ReviewGynecomastia: Clinical evaluation and managementGynaecomastia and breast cancer in menGynaecomastia--pathophysiology, diagnosis and treatmentMinimally invasive esthetic procedures of the male breast.Management of complications of prostate cancer treatment.Gynecomastia: physiopathology, evaluation and treatment.Tamoxifen for the management of breast events induced by non-steroidal antiandrogens in patients with prostate cancer: a systematic reviewMultimodality treatment of gynecomastia in patients receiving antiandrogen therapy for prostate cancer in the era of abiraterone acetate and new antiandrogen molecules.Drug-induced gynecomastia.Optimal prophylactic and definitive therapy for bicalutamide-induced gynecomastia: results of a meta-analysisSafety of antiandrogen therapy for treating prostate cancer.Bicalutamide 150 mg in addition to standard care for patients with early non-metastatic prostate cancer: updated results from the Scandinavian Prostate Cancer Period Group-6 Study after a median follow-up period of 7.1 years.Treatment of bicalutamide-induced breast events.Estrogenic side effects of androgen deprivation therapy.Gynecomastia - evaluation and current treatment optionsAromatase inhibitors in men: effects and therapeutic optionsProphylactic breast bud radiotherapy for patients taking bicalutamide: should this still be practised for patients with prostate cancer?Gynecomastia in patients with prostate cancer: update on treatment options.Optimizing outcomes and quality of life in the hormonal treatment of prostate cancer.Trends in primary androgen depletion therapy for patients with localized and locally advanced prostate cancer: Japanese perspective.Androgen deprivation therapy toxicity and management for men receiving radiation therapyIndirect androgen doping by oestrogen blockade in sports.Anastrozole for malignant and benign conditions: present applications and future therapeutic integrations.The pharmacotherapy of male hypogonadism besides androgens.Tamoxifen in men: a review of adverse events.Androgen receptor and heterogeneous nuclear ribonucleoprotein K colocalize in the nucleoplasm and are modulated by bicalutamide and 4-hydroxy-tamoxifen in prostatic cancer cell lines.Disruption of androgen and estrogen receptor activity in prostate cancer by a novel dietary diterpene carnosol: implications for chemoprevention.A proposal for the repositioning of prophylactic breast radiotherapy of prostate cancer patients.Management of senescent gynecomastia in the Veterans Health Administration.The Early Prostate Cancer program: bicalutamide in nonmetastatic prostate cancer.GynaecomastiaManagement of the side effects of androgen deprivation therapy in men with prostate cancerDrug-induced gynecomastia
P2860
Q21131717-1015CEBE-C05B-4D69-BA15-6E00E3BE69C5Q24568123-FD660759-4D63-4AC2-A49B-2A556048FFC1Q24648830-A576AD3D-C41B-4856-ACE2-16323E6335CFQ28245725-88666AC3-3CB6-404C-B86D-7561F4162369Q33925718-F020EE72-8ED6-4850-8FB3-F64BB72315F9Q33978360-32454DD3-A342-4B49-9111-F3DF0EFC546FQ34287744-EA08E60D-745B-4086-9D40-808ACBD3DCD6Q34296202-7716325C-BC6B-4893-AFFD-11E063696CAFQ34310067-086F710F-A864-4B3C-81BC-3F16B7D8661DQ34312712-70FFA676-A8ED-4226-BFD7-30119741792DQ34372251-25E120E9-69E6-45D3-83D9-85A2107494CBQ34441134-BE8CBCD6-E0E1-4D55-AF6C-FD84399D13B0Q34585070-CC9072B2-D62D-4BD9-A071-83B738205940Q34722383-5EE4904C-C429-44FE-86D9-BE47E64FFCC2Q34743239-7DDA5D0B-625C-4B5F-AB56-0FD2E5FAE686Q34764873-28ADFDFA-042E-46C2-946F-22534674260BQ35128738-55DE4F8D-64BA-4479-8FD8-95438BC36BB0Q36210503-BAB12A2A-25F1-4766-AEC1-FC1031ABA42DQ36375981-ADC876FA-6175-4771-994D-18574F8FAC3BQ36432836-CEF47601-0DA4-45BA-924F-0896ADD668A8Q36456013-F3EBD758-1F5F-4CB6-9033-034D3265E1A4Q36530136-BC2CACA4-1487-4B9B-A5AB-2BEC249227C8Q36736110-6CB1EE7E-82F6-4996-BA2A-96E95D2FA6FFQ36967279-5AD80DB7-F235-4636-8F36-54FED7E39EC1Q38293550-7CB76A4A-7928-4045-A167-567E608B50B2Q38827549-C581F8D3-8780-4979-8A24-BAE7E8EE4BF0Q39591979-72E0A3D7-956C-4CBC-9F66-CAEC6F23718AQ39663730-6A247B84-B545-4B38-BEFC-85BA2AD7A882Q40340176-BFF798F7-D3C8-4978-8E56-9EF610A96E7EQ45330736-DFA759AE-2DC0-4DC9-B92E-994A1BF6A70DQ46682601-B3A903C1-BD70-49B5-BD6D-E53EF0B41705Q54170800-1497D379-2E7D-4425-A057-8A2E7ED1BF0BQ57143367-D9B0F960-C298-4E28-8D0B-6999B440B6BBQ57258716-0DDA3458-0ADE-4137-B23F-B0D970DEF5F0
P2860
Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer.
description
2005 nî lūn-bûn
@nan
2005 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Evaluation of tamoxifen and an ...... onotherapy of prostate cancer.
@ast
Evaluation of tamoxifen and an ...... onotherapy of prostate cancer.
@en
Evaluation of tamoxifen and an ...... onotherapy of prostate cancer.
@nl
type
label
Evaluation of tamoxifen and an ...... onotherapy of prostate cancer.
@ast
Evaluation of tamoxifen and an ...... onotherapy of prostate cancer.
@en
Evaluation of tamoxifen and an ...... onotherapy of prostate cancer.
@nl
prefLabel
Evaluation of tamoxifen and an ...... onotherapy of prostate cancer.
@ast
Evaluation of tamoxifen and an ...... onotherapy of prostate cancer.
@en
Evaluation of tamoxifen and an ...... onotherapy of prostate cancer.
@nl
P2093
P356
P1476
Evaluation of tamoxifen and an ...... monotherapy of prostate cancer
@en
P2093
Bertaccini A
Boccardo F
Di Tonno P
Ferraris V
Macchiarella A
Manganelli A
P304
P356
10.1200/JCO.2005.12.013
P407
P577
2005-02-01T00:00:00Z